Campbell & CO Investment Adviser LLC Mannkind Corp Transaction History

Campbell & CO Investment Adviser LLC

  • $1.3 Billion
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024
SELL
$3.25 - $5.27 $12,272 - $19,899
-3,776 Reduced 12.71%
25,923 $117,000
Q4 2023

Feb 13, 2024
BUY
$3.34 - $4.29 $18,470 - $23,723
5,530 Added 22.88%
29,699 $108,000
Q3 2023

Nov 08, 2023
SELL
$3.91 - $5.45 $115,450 - $160,922
-29,527 Reduced 54.99%
24,169 $99,000
Q2 2023

Aug 11, 2023
BUY
$3.72 - $4.79 $16,457 - $21,190
4,424 Added 8.98%
53,696 $218,000
Q1 2023

May 11, 2023
SELL
$3.95 - $5.63 $19,706 - $28,088
-4,989 Reduced 9.19%
49,272 $202,000
Q4 2022

Feb 14, 2023
BUY
$3.02 - $5.37 $163,868 - $291,381
54,261 New
54,261 $285,000

Others Institutions Holding MNKD

# of Institutions
242
Shares Held
148M
Call Options Held
1.62M
Put Options Held
802K
View Full List

About MANNKIND CORP

MNKD Quotes by TradingView
  • Ticker MNKD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 257,338,000
  • Market Cap $1.55B
  • Description
  • MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...
More about MNKD
Track This Portfolio

Track Campbell & CO Investment Adviser LLC Portfolio

Follow Campbell & CO Investment Adviser LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

News

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email